Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 01-Mar-24 4:40 PM View:  | Tarriff Scott 10% Owner | Eagle Pharmaceuticals, Inc. (EGRX) | 28-Feb-24 | Payment of Exercise | 2,119 | $6.27 | $13,286.10 | (< 1%) 1.46M to 1.45M | |
| 29-Feb-24 4:44 PM View: | Tarriff Scott 10% Owner | Eagle Pharmaceuticals, Inc. (EGRX) | 27-Feb-24 | Payment of Exercise | 3,154 | $6.44 | $20,311.80 | (< 1%) 1.46M to 1.46M | |
| 29-Feb-24 4:44 PM View: | Tarriff Scott 10% Owner | Eagle Pharmaceuticals, Inc. (EGRX) | 27-Feb-24 | Grant | 12,950 | -- | -- | < 1% 1.45M to 1.46M | |
| 29-Feb-24 8:23 PM View: | Cahill Brian Joseph Chief Financial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 27-Feb-24 | Grant | 3,800 | -- | -- | 8% 45.75K to 49.55K | |
| 29-Feb-24 8:23 PM View: | Cahill Brian Joseph Chief Financial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 27-Feb-24 | Payment of Exercise | 1,589 | $6.44 | $10,233.20 | (3%) 49.55K to 47.96K | |
| 06-Feb-24 5:09 PM View: | Cahill Brian Joseph Chief Financial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 02-Feb-24 | Payment of Exercise | 934 | $5.85 | $5,463.90 | (2%) 46.68K to 45.75K | |
| 09-Jan-24 5:01 PM View: | Cahill Brian Joseph Chief Financial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 05-Jan-24 | Payment of Exercise | 735 | $5.13 | $3,770.55 | (2%) 47.42K to 46.68K | |
| 09-Jan-24 5:00 PM View: | Tarriff Scott 10% Owner | Eagle Pharmaceuticals, Inc. (EGRX) | 05-Jan-24 | Payment of Exercise | 4,322 | $5.13 | $22,171.90 | (< 1%) 1.54M to 1.53M | |
| 20-Dec-23 4:34 PM View: | Cahill Brian Joseph Chief Financial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 18-Dec-23 | Payment of Exercise | 452 | $4.76 | $2,151.52 | (< 1%) 47.87K to 47.42K | |
| 03-Nov-23 4:39 PM View: | Tarriff Scott CEO Director 10% Owner | Eagle Pharmaceuticals, Inc. (EGRX) | 02-Nov-23 | Sale (Planned) | 10,694 | $13.87 | $148,326.00 | (< 1%) 1.55M to 1.54M | |
| 03-Nov-23 4:39 PM View: | Tarriff Scott CEO Director 10% Owner | Eagle Pharmaceuticals, Inc. (EGRX) | 01-Nov-23 | Sale (Planned) | 10,925 | $13.82 | $150,984.00 | (< 1%) 1.56M to 1.55M | |
| 31-Oct-23 5:41 PM View: | Graves Michael Director | Eagle Pharmaceuticals, Inc. (EGRX) | 27-Oct-23 | Option Exercise | 9,360 | $4.94 | $46,238.40 | 936% 1.0K to 10.36K | |
| 04-Oct-23 5:07 PM View: | Tarriff Scott CEO Director 10% Owner | Eagle Pharmaceuticals, Inc. (EGRX) | 03-Oct-23 | Sale (Planned) | 10,734 | $14.46 | $155,174.00 | (< 1%) 1.57M to 1.56M | |
| 04-Oct-23 5:07 PM View: | Tarriff Scott CEO Director 10% Owner | Eagle Pharmaceuticals, Inc. (EGRX) | 02-Oct-23 | Sale (Planned) | 9,511 | $15.23 | $144,853.00 | (< 1%) 1.58M to 1.57M | |
| 18-May-23 5:22 PM View: | Tarriff Scott CEO Director 10% Owner | Eagle Pharmaceuticals, Inc. (EGRX) | 16-May-23 | Sale | 15,000 | $19.98 | $299,700.00 | (< 1%) 1.59M to 1.58M | |
| 15-May-23 8:34 PM View: | Tarriff Scott CEO Director 10% Owner | Eagle Pharmaceuticals, Inc. (EGRX) | 15-May-23 | Sale | 15,000 | $21.07 | $315,992.00 | (< 1%) 1.61M to 1.59M | |
| 15-May-23 8:34 PM View: | Tarriff Scott CEO Director 10% Owner | Eagle Pharmaceuticals, Inc. (EGRX) | 12-May-23 | Sale | 15,000 | $20.27 | $304,014.00 | (< 1%) 1.62M to 1.61M | |
| 15-May-23 8:34 PM View: | Tarriff Scott CEO Director 10% Owner | Eagle Pharmaceuticals, Inc. (EGRX) | 11-May-23 | Sale | 15,000 | $20.71 | $310,650.00 | (< 1%) 1.64M to 1.62M | |
| 02-Mar-23 4:20 PM View: | Cahill Brian Joseph Chief Financial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 01-Mar-23 | Grant | 18,500 | -- | -- | 63% 29.37K to 47.87K | |
| 02-Mar-23 4:18 PM View: | Tarriff Scott CEO Director 10% Owner | Eagle Pharmaceuticals, Inc. (EGRX) | 01-Mar-23 | Grant | 70,900 | -- | -- | 5% 1.57M to 1.64M | |
| 02-Mar-23 4:20 PM View: | Cahill Brian Joseph Chief Financial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 28-Feb-23 | Payment of Exercise | 718 | $28.00 | $20,104.00 | (2%) 30.09K to 29.37K | |
| 02-Mar-23 4:18 PM View: | Tarriff Scott CEO Director 10% Owner | Eagle Pharmaceuticals, Inc. (EGRX) | 28-Feb-23 | Payment of Exercise | 3,113 | $28.00 | $87,164.00 | (< 1%) 1.57M to 1.57M | |
| 06-Feb-23 4:48 PM View: | Cahill Brian Joseph Chief Financial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 02-Feb-23 | Payment of Exercise | 785 | $34.09 | $26,760.70 | (3%) 30.87K to 30.09K | |
| 31-Jan-23 6:21 PM View: | Cahill Brian Joseph Chief Financial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 30-Jan-23 | Payment of Exercise | 601 | $33.21 | $19,959.20 | (2%) 31.47K to 30.87K | |
| 24-Jan-23 6:13 PM View: | Tarriff Scott CEO Director 10% Owner | Eagle Pharmaceuticals, Inc. (EGRX) | 23-Jan-23 | Payment of Exercise | 3,732 | $33.64 | $125,544.00 | (< 1%) 1.58M to 1.57M | |
| 09-Jan-23 4:33 PM View: | Tarriff Scott CEO Director 10% Owner | Eagle Pharmaceuticals, Inc. (EGRX) | 05-Jan-23 | Payment of Exercise | 3,827 | $29.26 | $111,978.00 | (< 1%) 1.58M to 1.58M | |
| 09-Jan-23 4:34 PM View: | Cahill Brian Joseph Chief Financial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 05-Jan-23 | Payment of Exercise | 734 | $29.26 | $21,476.80 | (2%) 32.21K to 31.47K | |
| 21-Dec-22 4:17 PM View: | Cahill Brian Joseph Chief Financial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 19-Dec-22 | Payment of Exercise | 461 | $30.03 | $13,843.80 | (1%) 32.67K to 32.21K | |
| 08-Sep-22 5:08 PM View: | Edlin Richard A. Director | Eagle Pharmaceuticals, Inc. (EGRX) | 06-Sep-22 | Sale | 6,800 | $30.99 | $210,732.00 | (23%) 29.4K to 22.6K | |
| 02-Mar-22 6:09 PM View: | Cahill Brian Joseph Chief Financial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 28-Feb-22 | Grant | 8,000 | -- | -- | 32% 24.67K to 32.67K | |
| 02-Mar-22 6:11 PM View: | Moran Michael Shawn EVP, Chief Commercial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 28-Feb-22 | Grant | 10,400 | -- | -- | 48% 21.71K to 32.12K | |
| 02-Mar-22 6:02 PM View: | Tarriff Scott CEO Director 10% Owner | Eagle Pharmaceuticals, Inc. (EGRX) | 28-Feb-22 | Grant | 34,800 | -- | -- | 2% 1.54M to 1.58M | |
| 04-Feb-22 4:57 PM View: | Moran Michael Shawn EVP, Chief Commercial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 02-Feb-22 | Payment of Exercise | 742 | $45.03 | $33,412.30 | (3%) 22.46K to 21.71K | |
| 04-Feb-22 4:58 PM View: | Cahill Brian Joseph Chief Financial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 02-Feb-22 | Payment of Exercise | 805 | $45.03 | $36,249.10 | (3%) 25.47K to 24.67K | |
| 01-Feb-22 6:46 PM View: | Moran Michael Shawn EVP, Chief Commercial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 31-Jan-22 | Payment of Exercise | 210 | $45.94 | $9,647.40 | (< 1%) 22.67K to 22.46K | (14%) |
| 01-Feb-22 6:45 PM View: | Cahill Brian Joseph Chief Financial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 31-Jan-22 | Payment of Exercise | 626 | $45.94 | $28,758.40 | (2%) 26.1K to 25.47K | (14%) |
| 11-Jan-22 4:42 PM View: | Moran Michael Shawn EVP, Chief Commercial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 07-Jan-22 | Payment of Exercise | 90 | $50.63 | $4,556.70 | (< 1%) 22.76K to 22.67K | (4%) |
| 11-Jan-22 4:40 PM View: | Cahill Brian Joseph Chief Financial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 07-Jan-22 | Payment of Exercise | 263 | $50.63 | $13,315.70 | (< 1%) 26.36K to 26.1K | (4%) |
| 07-Jan-22 4:37 PM View: | Cahill Brian Joseph Chief Financial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 05-Jan-22 | Payment of Exercise | 738 | $50.69 | $37,409.20 | (3%) 27.1K to 26.36K | (1%) |
| 07-Jan-22 4:39 PM View: | Moran Michael Shawn EVP, Chief Commercial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 05-Jan-22 | Payment of Exercise | 1,511 | $50.69 | $76,592.60 | (6%) 24.27K to 22.76K | (1%) |
| 21-Dec-21 7:10 PM View: | Cahill Brian Joseph Chief Financial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 20-Dec-21 | Payment of Exercise | 467 | $55.42 | $25,881.10 | (2%) 27.57K to 27.1K | 0% |
| 12-Apr-21 4:38 PM View: | Ratoff Steven B Director | Eagle Pharmaceuticals, Inc. (EGRX) | 08-Apr-21 | Option Exercise | 7,020 | $7.33 | $51,433.20 | 35% 20.34K to 27.36K | |
| 05-Apr-21 4:54 PM View: | Tarriff Scott CEO Director 10% Owner | Eagle Pharmaceuticals, Inc. (EGRX) | 01-Apr-21 | Option Exercise | 31,201 | $8.78 | $273,945.00 | 2% 1.53M to 1.56M | |
| 05-Apr-21 4:54 PM View: | Tarriff Scott CEO Director 10% Owner | Eagle Pharmaceuticals, Inc. (EGRX) | 01-Apr-21 | Payment of Exercise | 16,278 | $41.87 | $681,560.00 | (1%) 1.56M to 1.54M | |
| 05-Apr-21 4:54 PM View: | Tarriff Scott CEO Director 10% Owner | Eagle Pharmaceuticals, Inc. (EGRX) | 23-Feb-21 | Gift | 16,340 | -- | -- | (1%) 1.55M to 1.53M | |
| 04-Feb-21 5:09 PM View: | Cahill Brian Joseph Chief Financial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 02-Feb-21 | Grant | 8,900 | -- | -- | 48% 18.67K to 27.57K | |
| 04-Feb-21 5:18 PM View: | Pernock David Pres & Chief Operating Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 02-Feb-21 | Grant | 9,700 | -- | -- | 22% 44.92K to 54.63K | |
| 04-Feb-21 5:15 PM View: | Ng-Cashin Judith Chief Medical Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 02-Feb-21 | Grant | 2,000 | -- | -- | 100% 0 to 2.0K | |
| 02-Feb-21 5:08 PM View: | Cahill Brian Joseph Chief Financial Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 29-Jan-21 | Payment of Exercise | 637 | $46.67 | $29,728.80 | (3%) 19.3K to 18.67K | (4%) |
| 26-Jan-21 6:32 PM View: | Pernock David Pres & Chief Operating Officer | Eagle Pharmaceuticals, Inc. (EGRX) | 23-Jan-21 | Payment of Exercise | 1,892 | $47.70 | $90,248.40 | (4%) 46.82K to 44.92K | (2%) |
